1. Lee G, Arcasoy MO. The clinical and laboratory evaluation of the patient with erythrocytosis.

Eur J
Intern Med. 2015;26(5):297-302.
2. McMullin MF, Wilkins BS, Harrison CN. Management of polycythemia vera: A critical review of
current data. British Journal of Hematology. 2015;172(3):337-49.
3. Tefferi A. Clinical manifestation and diagnosis of polycythemia vera. Waltham: Uptodate; 2019.
4. Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ.
2013;347:f6667.
5. Maffioli M, Mora B, Passamonti F. Polycythemia vera: From New, Modified Diagnostic Criteria to
New Therapeutic Approaches. Clinical Advances in Hematology & Oncology. 2017;15(9):700-7
6. Srikanth N. Polycythemia Vera. Medscape [Online]. Available from URL:
https://emedicine.medscape.com/article/205114-overview
7. Aljabry MS. Primary familial and congenital polycythemia; The forgotten entity. JAppl Hematol
2018;9:39-44. DOI: 10.4103/joah.joah_30_18
8. Keohane C, McMullin MF, Harrison C. The diagnosis and management of erythrocytosis. BMJ
2013; 347:f6667. doi: https: //doi.org /10.1136 /bmj.f6667
9. Srikanth N. Secondary Polycythemia. Medscape [Online]. Available from URL:
https://emedicine.medscape.com/article/205039-overview
10. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis,
risk-stratification, and management. American Journal of Hematology, 2016. 92(1): 94–108.
doi:10.1002/ajh.24607
11. Prenggono D. Polisitemia Vera Buku Ajar Ilmu Penyakit Dalam Jilid II. Edisi IV. Penerbit IPD
FKUI. 2006: 702-705.
12. Supandiman I, Sumahtri R. Polisitemia Vera. Pedoman Diagnosis dan terapi Hematologi Onkologi
Medik. 2003: 83-90
13. Tefferi A, Rumi E, Finazzi G, et al.Survival and prognosis among 1545 patients with contemporary
polycythemia vera: an international study. Leukemia 2013;27(9):1874-1881.
14. Moulard O, Mehta J.Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia
vera in the European Union.European journal of haematology 2014;92(4):289-297.
15. Landolfi, R., L. Di Gennaro.Pathophysiology of thrombosis in myeloproliferative neoplasms.
Haematologica 2011;96(2):183-186.
16. Ma X, Vanasse G, Cartmel B, Wang Y and Selinger HA. Prevalence of polycythemia vera and
essential thrombocythemia. Am. J. Hematol. 2008 May;83(5):359-62.
17. Zivot A, Lipton JM, Narla A, Blanc L. Erythropoiesis: Insights into pathophysiology and treatments
in 2017. Molecular Med. 2018;24(1):11
18. Greenfield G, McPherson S, Mills K, McMullin MF. The ruxolitinib effect: Understanding how
molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in
myeloproliferative neoplasms. Journal of Translational Medicine. 2018;16:360
19. Milosevic JD, Kralovics R. Genetic and epigenetic alterations of myeloproliferative disorders. Int J
Hematol. 2013;97:183-97
20. U.S National Library of Medicine. Genetics Home Reference [Internet]. 2019 [cited 2019 March 27.
Available from: https://ghr.nlm.nih.gov/gene/JAK2
21. Helbig G. Classical Philadelphia-negative myeloproliferative neoplasms: Focus on mutations and
JAK2 inhibitors. Medical Oncology. 2018;35(9):119
22. de Freitas RM, Maranduba CMdC. Myeloproliferative neoplasms and the JAK/STAT signaling
pathway: an overview. Revista Brasileira de Hematologia e Hemoterapia. 2015;37(5):348-53.
23. McMullin MF, Harrison CN, Ali S, et al. A guideline for the diagnosis and management of
polycythaemia vera. A British Society for Haematology Guideline. British Journal of Haematology,
2018. doi:10.1111/bjh.15648
24. Barbui T, Thiele J, Gisslinger H, Finazzi G, Vannucchi AM, Tefferi A. The 2016 revision of WHO
classification of myeloproliferative neoplasm/MPN: Clinical and molecular advances. Blood Rev.
2016;30(6):453–459.
25. Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis,
risk-stratification and management. Am Journal Hematol. 2015 ;90(2):162–173
26. Anunayi J,Motrapu ML,Monasiddiqui, et al.Polycythemia Vera in a Young Adult: A Rare Case
Report. Sch J Med Case Rep 2014;2 (4):2.
27. Raedler LA. Diagnosis and management of polycythemia vera: proceedings from a multidisciplinary
roundtable. Am Health Drug Benefits. 2014 Oct;7(7 Suppl 3):S36-47.
28. Vannucchi AM. How I treat polycythemia vera. Blood. 2014;124:3212-20
29. Pillai AA, Babiker HM. Polycythemia. [Updated 2019 May 5]. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2019 Jan-. Available
from:https://www.ncbi.nlm.nih.gov/books/NBK526081
30. Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera treatment algorithm 2018. Blood Cancer J.
2018;8:3
31. Ibrahim IK, Hassan R, Ali EW, Omer A. Polycythaemia vera among Sudanese patients with special
emphasis on JAK2 mutations. Asian Pac J Cancer Prev. 2019;20(1):41-44
32. Singh A, Xu YJ. The cell killing mechanisms of hydroxyurea. Genes. 2016;7(11):99
33. Hasselbalch HC, Holmström MO. Perspectives on interferon-alpha in the treatment of polycythemia
vera and related myeloproliferative neoplasms: Minimal residual disease and cure? Seminars in
Immunopathology. 2019;41(1):5-19